drugset / Trial / NCT01962363
EPI-743 in Friedreich's Ataxia Point Mutations
Phase 2
Completed
4 enrolled
University of South Florida
Edison Pharmaceuticals Inc · collabFriedreich's Ataxia Research Alliance · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the effects of EPI-743 in patients with Friedreich's Ataxia point mutations
Timeline
- Start
- 2013-10
- Primary completion
- 2016-06
- Completion
- 2016-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vatiquinone | Small molecule | 400 mg | Oral |